Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2020 Aug 28

PMID 32851949

Citations 7

Authors

Vimal Patel

Vishal Chavda

Jigar Shah

Affiliations

Soon will be listed here.

Abstract

Neurology and associated nanotherapeutics are a complex field in terms of therapeutics and neurological disorder complexity. The brain is an intricate appendage and requires more precise embattled treatment for the particular diseases and hence it is a broad scale for developing more targeted drug deliveries. The brain is one of the most inaccessible tissues of the body due to the existence of the blood-brain barrier (BBB), thus delivery of drugs inside the brain is a striking dare and it is also tricky to treat central nervous system (CNS) complications pharmacologically. The therapeutic aspiration is to accomplish the lowest drug meditation in the brain tissues so as to gain favoured therapeutic results. To devastate this obstacle, nanotechnology is engaged in the field of targeted brain drug delivery and neuropathology targeting. These carriers hold myriad abilities as they may augment the drug delivery into the brain by shielding them from degradation and prolonging their transmission in the blood, as well as promoting their transport through the BBB. Nanopharmaceuticals are quickly sprouting as a new avenue that is engaged with the drug-loaded nanocarriers to demonstrate unique physicochemical properties and tiny size range for penetrating the central nervous system. The enchantment behind their therapeutic achievement is the condensed drug dose and inferior toxicity, whereby restricting the therapeutic compound to the specific site. Therefore, in this article, we have tried to recapitulate the advances of the novel scopes for the brain targeted drug delivery for complex neurological disorders.

Citing Articles

Revolutionizing Neuroimmunology: Unraveling Immune Dynamics and Therapeutic Innovations in CNS Disorders.

Toader C, Tataru C, Munteanu O, Covache-Busuioc R, Serban M, Ciurea A Int J Mol Sci. 2025; 25(24.

PMID: 39769374 PMC: 11728275. DOI: 10.3390/ijms252413614.

Advancements in nanotheranostics for glioma therapy.

Sahoo L, Paikray S, Tripathy N, Fernandes D, Dilnawaz F Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39480526 DOI: 10.1007/s00210-024-03559-w.

Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development.

Majumdar M, Badwaik H Curr Drug Targets. 2024; 25(15):987-1011.

PMID: 39313872 DOI: 10.2174/0113894501312703240826070530.

Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment.

Rahban M, Joushi S, Bashiri H, Saso L, Sheibani V Front Chem. 2024; 11:1325214.

PMID: 38264122 PMC: 10804459. DOI: 10.3389/fchem.2023.1325214.

Nano biomaterials based strategies for enhanced brain targeting in the treatment of neurodegenerative diseases: an up-to-date perspective.

Nayab D, Din F, Ali H, Kausar W, Urooj S, Zafar M J Nanobiotechnology. 2023; 21(1):477.

PMID: 38087359 PMC: 10716964. DOI: 10.1186/s12951-023-02250-1.

References

Pardridge . Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. Pharm Sci Technol Today. 1999; 2(2):49-59. DOI: 10.1016/s1461-5347(98)00117-5. View

Yang Z, Li J, Wang Z, Dong D, Qi X . Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 2014; 35(19):5226-39. DOI: 10.1016/j.biomaterials.2014.03.017. View

Wong H, Wu X, Bendayan R . Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev. 2011; 64(7):686-700. DOI: 10.1016/j.addr.2011.10.007. View

de Boer A, Gaillard P . Strategies to improve drug delivery across the blood-brain barrier. Clin Pharmacokinet. 2007; 46(7):553-76. DOI: 10.2165/00003088-200746070-00002. View

Lin L, Cai J, Jiang C . Recent Advances in Targeted Therapy for Glioma. Curr Med Chem. 2016; 24(13):1365-1381. DOI: 10.2174/0929867323666161223150242. View

Palma E, Pasqua A, Gagliardi A, Britti D, Fresta M, Cosco D . Antileishmanial Activity of Amphotericin B-loaded-PLGA Nanoparticles: An Overview. Materials (Basel). 2018; 11(7). PMC: 6073796. DOI: 10.3390/ma11071167. View

Canavese G, Ancona A, Racca L, Canta M, Dumontel B, Barbaresco F . Nanoparticle-assisted ultrasound: A special focus on sonodynamic therapy against cancer. Chem Eng J. 2019; 340:155-172. PMC: 6420022. DOI: 10.1016/j.cej.2018.01.060. View

Das S, Carnicer-Lombarte A, Fawcett J, Bora U . Bio-inspired nano tools for neuroscience. Prog Neurobiol. 2016; 142:1-22. DOI: 10.1016/j.pneurobio.2016.04.008. View

Saunders N, Habgood M, Mollgard K, Dziegielewska K . The biological significance of brain barrier mechanisms: help or hindrance in drug delivery to the central nervous system?. F1000Res. 2016; 5. PMC: 4786902. DOI: 10.12688/f1000research.7378.1. View

10.

Chu C, Liu G, Janowski M, Bulte J, Li S, Pearl M . Real-Time MRI Guidance for Reproducible Hyperosmolar Opening of the Blood-Brain Barrier in Mice. Front Neurol. 2018; 9:921. PMC: 6212512. DOI: 10.3389/fneur.2018.00921. View

11.

Ruan S, Yuan M, Zhang L, Hu G, Chen J, Cun X . Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. Biomaterials. 2014; 37:425-35. DOI: 10.1016/j.biomaterials.2014.10.007. View

12.

Gao K, Jiang X . Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm. 2006; 310(1-2):213-9. DOI: 10.1016/j.ijpharm.2005.11.040. View

13.

Bobo D, Robinson K, Islam J, Thurecht K, Corrie S . Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016; 33(10):2373-87. DOI: 10.1007/s11095-016-1958-5. View

14.

Agarwal N, Jain S, Nagpal D, Agarwal N, Mediratta P, Sharma K . Liposomal formulation of curcumin attenuates seizures in different experimental models of epilepsy in mice. Fundam Clin Pharmacol. 2011; 27(2):169-72. DOI: 10.1111/j.1472-8206.2011.01002.x. View

15.

Malamatari M, Taylor K, Malamataris S, Douroumis D, Kachrimanis K . Pharmaceutical nanocrystals: production by wet milling and applications. Drug Discov Today. 2018; 23(3):534-547. DOI: 10.1016/j.drudis.2018.01.016. View

16.

Krol S . Challenges in drug delivery to the brain: nature is against us. J Control Release. 2012; 164(2):145-55. DOI: 10.1016/j.jconrel.2012.04.044. View

17.

Zhang P, Hu L, Yin Q, Zhang Z, Feng L, Li Y . Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation. J Control Release. 2012; 159(3):429-34. DOI: 10.1016/j.jconrel.2012.01.031. View

18.

Md S, Khan R, Mustafa G, Chuttani K, Baboota S, Sahni J . Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci. 2012; 48(3):393-405. DOI: 10.1016/j.ejps.2012.12.007. View

19.

Haque S, Md S, Fazil M, Kumar M, Sahni J, Ali J . Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation. Carbohydr Polym. 2014; 89(1):72-9. DOI: 10.1016/j.carbpol.2012.02.051. View

20.

Gao H . Perspectives on Dual Targeting Delivery Systems for Brain Tumors. J Neuroimmune Pharmacol. 2016; 12(1):6-16. DOI: 10.1007/s11481-016-9687-4. View